Background Paediatric multidrug-resistant (MDR) tuberculosis is a public health challenge of growing concern, accounting for an estimated 15% of all global cases of MDR tuberculosis. Clinical management is especially challenging, and recommendations are based on restricted evidence. We aimed to assess existing evidence for the treatment of MDR tuberculosis in children.
Introduction
An estimated 12 million people worldwide have tuberculosis, of whom about 650 000 have multidrug-resistant (MDR) disease. 1 Childhood tuberculosis is estimated to account for 10-15% of the global tuberculosis burden, 2 and probably accounts for a similar proportion when considering only drug-resistant disease. The highest rates of paediatric MDR tuberculosis are reported in lowincome countries, 2 and in some regions the incidence of MDR tuberculosis has risen sharply in the past two decades-eg, in the Western Cape, South Africa, the proportion of culture-confi rmed cases of tuberculosis with multidrug-resistance has tripled in the past 15 years from 2·3% to 7·3%. 3 MDR tuberculosis is underdetected in children. Diagnosis of drug resistance needs mycobacterial culture and drug susceptibility testing (DST), 4 but the diffi culty in obtaining respiratory secretions, such as sputum or gastric aspirates, or specimens of extrapulmonary tuber culosis from young children, 5 along with the fact that up to half of all children with a clinical diagnosis of tuberculosis disease are smearnegative and culture-negative, makes microbiological confi rmation challenging. 6 Strict programmatic requirements for microbiological confi rmation of drug resistance com bined with insuffi cient recognition of the importance of taking into account DST patterns from adult source cases can lead to substantial delays in diagnosis and initiation of appropriate treatment. 7 These delays could lead to progression of disease, increased risk of infectiousness of children, greater risk of disease complications such as tuberculous meningitis, and higher rates of morbidity and mortality. 8, 9 Paediatric drug-resistant tuberculosis is a neglected concern, with few children being treated relative to the estimated disease burden. 10 WHO guidelines for the treatment of drug-resistant tuberculosis in adults are based on evidence from meta-analyses of individual patients' data. 11 However, recommendations for children are based on expert opinion, drawing on data from case series and cohort studies, 12, 13 often with small sample sizes. Consequently, variation exists in program matic choices of treatment regimens, with the choice of drugs informed by previous drug exposure and DST results. 14 Because of uncertainties about diagnosis and the best treatment regimens, and concerns about the toxic eff ects associated with MDR tuberculosis treatment, health-care providers are cautious about treating paediatric MDR tuberculosis.
We did a systematic review and meta-analysis of the available evidence for treatment outcomes in children with MDR tuberculosis, and assessed the characteristics of patients and studies that could have aff ected treatment success.
Methods

Search strategy and selection criteria
We searched for publications in PubMed, Ovid, Embase, Cochrane Library, PsychINFO, and BioMedCentral databases up to Oct 31, 2011. We developed a highly sensitive search strategy, using a combination of the search terms "tuberculosis", "multidrug resistance", "multidrugresistant", "treatment outcomes", and "children", both as exploded MESH headings and free-text terms. We reviewed the bibliographies of all retrieved articles. We also searched all electronically available conference abstracts from the International Union Against Tuberculosis and Lung Disease . Authors of relevant studies were contacted for clarifi cation and additional information when necessary. We applied no language restriction to our search of abstracts.
Two investigators (DE, NF) reviewed all abstracts and full-text articles, with fi nal inclusion decided through consensus. In cases of disagreement, consensus was achieved through third-party arbitration (GSC), including verifi cation with the study authors when needed. Studies were eligible if they included more than fi ve children (aged ≤16 years) within a defi ned treatment cohort. In anticipation of a paucity of data, case series of fi ve or more children were also included. Patients meeting the following criteria were viewed as having MDR tuberculosis: Patients meeting the following criteria were viewed as having MDR tuberculosis: the provision of second-line drugs together with either clinical evidence of tuberculosis and a known contact with MDR disease or confi rmed MDR DST result from a Mycobacterium tuberculosis isolate.
Data extraction
We extracted data from the eligible studies independently and in duplicate. Our primary outcome was treatment success. We recorded treatment outcomes according to WHO classifi cations of treatment success (cure, completion, or both), death, and default (defi ned as all patients lost to follow-up).
11 Success was defi ned as a composite of cure and treatment completion as defi ned by the studies. Intermediate outcomes were probable cure or failure according to the investigator's classifi cation and were subsequently added to the success and failure categories, respectively. All patients transferred out of the reporting treatment facility were regarded as having defaulted treatment, consistent with other MDR tuberculosis outcome reviews. 15 Secondary outcomes were death, defaulting, and adverse events. For each study we collected information about the charac teristics of patients (age, HIV status, previous treatment, and drug resistance), studies (setting, treatment protocols, average number of drugs in the regimen, treatment duration, length of follow-up, and whether the treatment was individualised or stand ardised), and study outcome defi nitions. We extracted the following information as determinants of study quality that could have aff ected treatment success: delivery of individualised treatment regimens guided by DST, use of injectable drugs, admission to hospital at the initiation of treatment, treatment completion rates, and provision of treatment support.
Statistical analysis
We calculated point estimates and 95% CIs for the proportion of patients achieving treatment success and the frequency of adverse outcomes. Treatment success was estimated conservatively, with all treatment defaults regarded as treatment failures. We stabilised the variance of the raw proportions using a Freeman-Tukey-type arcsine square-root transformation 16 and calculated pooled estimates using a DerSimonian and Laird random-eff ects model. 17 We ran a sensitivity analysis on our primary outcome using a Bayesian random-eff ects model with Monte Carlo Markov chain simulations of variability. 18 We calculated the τ² statistic to assess the proportion of overall variation attributable to betweenstudy heterogeneity, because this measure is less sensitive to the number of studies, 19 and explored potential sources of heterogeneity with univariate sensitivity analyses with χ² to estabish the potential eff ect of the following covariates: DST confi rmatory testing (≤50% or >50% of the cohort), treatment duration (≤ 18 months or >18 months), use of injectable drugs (≤80% or >80% of the cohort), age (≤ 5 years or >5 years), and HIV status (≤30% or >30% of the cohort). All p values are two-sided, and a p value of less than 0·05 was regarded as signifi cant. We did analyses using Stata (version 12) and MetaAnalyst (version Beta 3.13).
Role of the funding source
There was no funding source for this study. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The eight studies included in our analysis (fi gure 1) came from individual treatment programmes from fi ve countries (Peru, 20 Spain, 21 the USA, 22, 23 South Africa, 7, 24, 25 and Latvia 26 ) and reported on treatment outcomes for a range of eight patients 21 to 111 patients. 24 One study was a conference abstract; 26 the rest were published as full text articles.
Studies were done in a range of settings, including countries with high 7, 21, 24, 25 and low 17, 22, 23, 26 MDR tuberculosis burdens. The median age of children ranged from 25 months 25 to 132 months 20 and HIV seropositivity ranged from 0% 22 to 54% (table 1) . 25 In four studies, most children were reported to have been in contact with an adult with MDR tuberculosis (table 1) . 7, [20] [21] [22] The proportion of previously treated patients ranged from 0% 21 to 87% 20 (table 1) .Duration of treatment ranged from 6 months to 34 months, 22 and in most studies treatment was provided for a minimum of 18 months, which is consistent with WHO recommendations (table 2) . 7, 20, 22, 24 Median duration of follow-up, reported by four studies, ranged from 12 months 25 to 36·7 months (table 2) . 7 Time to appropriate treatment varied from 2 days 7 to 46 months. 20 All studies provided individualised treatment regimens guided by DST and reported high rates of treatment completion, and most studies 7, [20] [21] [22] [24] [25] [26] provided injectable drugs to most patients (table 2) . For most patients, treatment was initiated in hospital (table 2) . 7, 20, 21, [23] [24] [25] Insuffi cient data were available for outcomes for treatment with extensively drug-resistant tuberculosis to be included in this review.
Across all studies that used second-line drugs in individualised protocols (315 children), most children had 25 Schaaf et al (2003) 7 Granich et al (2005) 23 Drobac et al (2005) 20 Seddon et al (2011) 24 Feja et al (2008) 22 Lemaine et al (2009) 21 Feja et al (2008) 22 Lemaine et al (2009) 26 Fairlie et al (2011) 25 Seddon 21 Feja et al (2008) 22 Lemaine et al (2009) 26 Fairlie et al (2011) 25 Seddon et al (2011) proportion of children having an adverse event of 39·05% (28·7-49·4; fi gure 3). In most studies, children were screened clinically on a regular basis (of varying regularity in the diff erent studies), with investigations requested if any concerns were raised. The most frequently reported drug-related adverse event was nausea (table 3) . Other serious adverse events were hearing loss, psychiatric eff ects, and hypothyroidism. For minor adverse events, treatment could largely be continued without the need to stop any drugs. For the more severe adverse events, treatment with the drug thought to be causing the adverse eff ect was discontinued, and the patient was switched to an alternative treatment.
Discussion
Our systematic review suggests that MDR tuberculosis can be successfully treated in children, with the overall proportion of children achieving treatment success as good as, if not better than, that reported for adults receiving individualised treatment regimens (64%).
15
Mortality and defaulting seemed to be lower for children than for adults, but these diff erences were not statistically signifi cant. Detailed data for adverse events were absent from some studies, and adverse events were not systematically recorded in most studies. Nevertheless, more than a third of children had adverse events. This fi nding draws attention to the urgent need for more eff ective drugs, paediatric formulations of drugs, and a better understanding of the best possible dosing in children. Previous studies have reported a lower incidence of adverse events to second-line drugs in children than in adults. 27 In one study, 28 investigators compared incidences of adverse events between adults and children, recording rates of gastritis and psychiatric eff ects in adults to be about three times that of children who received similarly aggressive individualised regimens within the same series. We were unable to compare the prevalence of adverse events for children and adults because summary estimates were not available for adults. 15, 29 In line with expert opinion 30 and reviews, 31 our subgroup analysis suggested that the use of injectable drugs was associated with improved treatment outcomes for paediatric MDR tuberculosis. The best possible duration of treat ment for MDR tuberculosis is not established, and recom mendations are largely based on expert opinion. 30 The duration of treatment reported for children in this review was on average less than that reported for adults. 15, 27 The paucibacillary nature of MDR tuberculosis in many children implies that bacillary clearance can be faster in children than in adults, 7 although one of the studies included in this study had very high rates of smear-positive disease, most likely because of progression of disease before MDR tuberculosis was diagnosed. 24 Shortening treatment duration is an important goal for MDR tuberculosis management programmes, 32 and fewer drugs and shorter treatment durations (12 months compared with 18 months for adults) can potentially suffi ce in early, non-extensive childhood disease. 33 Future research should further assess the potential for shorter treatment as a method to limit costs and adverse events, especially because improvements in diagnostics might increase the number of individuals needing treatment. 34 The average time to initiation of appropriate treatment ranged from 2·5 months to 9·2 months, with the long delays probably caused by challenges in the confi rmation of diagnosis. Such delays before appropriate treatment draw attention to the need to develop rapid, reliable, and aff ordable tuberculosis diagnostics for children. 35 If programmes were to treat more children and need less stringent proof of MDR tuberculosis, then treatment could be started earlier for children, which might improve outcomes. For this to happen, substantial changes in treatment practices would be needed, whereby children with clinical tuberculosis and an MDR contact would be initiated on MDR tuberculosis treatment while awaiting micro biological test results with the assumption that the disease is likely to be MDR tuberculosis. At present, such children are started on fi rst-line treatment while waiting for microbiological drug-resistant confi rmation or clinical failure. However, because available drugs are associated with a high frequency of adverse events, such a strategy might become more feasible when new, less toxic drugs become available.
Our study has several strengths and limitations. We used a random-eff ects analysis and subgroup analyses in anticipation of heterogeneity. We also used a broad and inclusive search strategy, but cannot rule out the risk of publication bias. Several limitations also exist in the available evidence base. All studies included in our analysis were observational, and thus subject to potential bias as a result of unmeasured variables that could have aff ected outcomes, such as level of healthcare provider, and programme inputs (eg, such as material and social support for patients). Another limitation is that we were able to do a meta-analysis of only aggregate data; a meta-analysis of individual patients' data could be expected to provide further information about clinical determinants of treatment success. 36 The small amount of data from a few published paediatric cohorts leads to poor precision of overall estimates and limits the generalisability of fi ndings. Nevertheless, the decision to pool data through metaanalysis was based on the value of the provision of a more precise estimate for treatment success compared with that reported by individual studies. 37 Programmes should be encouraged to report outcomes to improve the knowledge base for care, especially because new drugs will become available. Although major adverse events are likely to be well recorded, 38 under-reporting of minor toxic eff ects in observational studies might lead to underestimation in our meta-analysis. Generally, however, estimates of the frequency of adverse events derived from observational studies are equivalent to those reported from trials. 38 Another limitation is the diffi culty in identifying the drug that causes a particular adverse event, because children were treated with multiple drugs with overlapping toxicities.
Our fi ndings draw attention to the urgent need to encourage more reporting of outcomes for children with MDR tuberculosis. We identifi ed several reports that had to be excluded because data were not clearly disaggregated by age, which was a missed opportunity. 39, 40 Furthermore, the discrepancies in the recording of study characteristics for paediatric treatment regimens draws attention to the need for the standardisation of the data collection process and reporting in programmes of childhood tuberculosis. 41 Although substantial progress has been made in the harmonisation of the defi nitions of cure for adult MDR tuberculosis during the period covering the included studies, 42 the defi nition is not suitable for paediatric disease. The absence of this defi nition means that study comparisons need to be interpreted with caution and that a standardised defi nition is needed to improve the comparability of the results of future research and programme assessments. Nevertheless, the results of our study should provide encouragement to health-care providers treating children with MDR tuberculosis that successful outcomes can be achieved, possibly with greater frequency than for adults.
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